Cargando…

Does the biomarker search paradigm need re-booting?

The clinical problem of bladder cancer is its high recurrence and progression, and that the most sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient compliance. Biomarkers for recurrence and progression could make a great contribution, but in spite of dec...

Descripción completa

Detalles Bibliográficos
Autor principal: Hurst, Robert E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654904/
https://www.ncbi.nlm.nih.gov/pubmed/19250539
http://dx.doi.org/10.1186/1471-2490-9-1
_version_ 1782165419247796224
author Hurst, Robert E
author_facet Hurst, Robert E
author_sort Hurst, Robert E
collection PubMed
description The clinical problem of bladder cancer is its high recurrence and progression, and that the most sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient compliance. Biomarkers for recurrence and progression could make a great contribution, but in spite of decades of research, no biomarkers are commercially available with the requisite sensitivity and specificity. In the post-genomic age, the means to search the entire genome for biomarkers has become available, but the conventional approaches to biomarker discovery are entirely inadequate to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity and specificity equal to that of cystoscopy is a problem of systems biology.
format Text
id pubmed-2654904
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26549042009-03-13 Does the biomarker search paradigm need re-booting? Hurst, Robert E BMC Urol Commentary The clinical problem of bladder cancer is its high recurrence and progression, and that the most sensitive and specific means of monitoring is cystoscopy, which is invasive and has poor patient compliance. Biomarkers for recurrence and progression could make a great contribution, but in spite of decades of research, no biomarkers are commercially available with the requisite sensitivity and specificity. In the post-genomic age, the means to search the entire genome for biomarkers has become available, but the conventional approaches to biomarker discovery are entirely inadequate to yield results with the new technology. Finding clinically useful biomarker panels with sensitivity and specificity equal to that of cystoscopy is a problem of systems biology. BioMed Central 2009-02-27 /pmc/articles/PMC2654904/ /pubmed/19250539 http://dx.doi.org/10.1186/1471-2490-9-1 Text en Copyright © 2009 Hurst; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Hurst, Robert E
Does the biomarker search paradigm need re-booting?
title Does the biomarker search paradigm need re-booting?
title_full Does the biomarker search paradigm need re-booting?
title_fullStr Does the biomarker search paradigm need re-booting?
title_full_unstemmed Does the biomarker search paradigm need re-booting?
title_short Does the biomarker search paradigm need re-booting?
title_sort does the biomarker search paradigm need re-booting?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654904/
https://www.ncbi.nlm.nih.gov/pubmed/19250539
http://dx.doi.org/10.1186/1471-2490-9-1
work_keys_str_mv AT hurstroberte doesthebiomarkersearchparadigmneedrebooting